An update on the development of novel antifungal agents for eumycetoma

David J Chandler; Alexandro Bonifaz; Wendy W J van de Sande

doi:10.3389/fphar.2023.1165273

An update on the development of novel antifungal agents for eumycetoma

Front Pharmacol. 2023 May 18:14:1165273. doi: 10.3389/fphar.2023.1165273. eCollection 2023.

Authors

David J Chandler^{1

2}, Alexandro Bonifaz³, Wendy W J van de Sande⁴

Affiliations

¹ Department of Global Health and Infection, Brighton and Sussex Medical School, Brighton, United Kingdom.
² Dermatology Department, Brighton General Hospital, University Hospitals Sussex NHS Foundation Trust, Brighton, United Kingdom.
³ Hospital General de México "Dr. Eduardo Liceaga", Mexico City, Mexico.
⁴ Erasmus MC, University Medical Center Rotterdam, Department of Medical Microbiology and Infectious Diseases, Rotterdam, Netherlands.

Abstract

Eumycetoma, a chronic subcutaneous mycosis, responds poorly to the available antifungal treatments and patients often require extensive surgical resection or amputation of the affected limb. More effective treatments are needed for eumycetoma. This article will describe some of the approaches being used to develop and evaluate new treatments for eumycetoma, summarise the latest developments and discuss the challenges that lie ahead.

Keywords: Madurella mycetomatis; Neglected Tropical Disease (NTD); eumycetoma; mycology; skin NTDs.

Publication types

Review